These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38471796)

  • 1. Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer.
    Danielli SG; Wurth J; Morice S; Kisele S; Surdez D; Delattre O; Bode PK; Wachtel M; Schäfer BW
    Mol Cancer Ther; 2024 Jun; 23(6):864-876. PubMed ID: 38471796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.
    Chen TJ; Mydel P; Benedyk-Machaczka M; Kamińska M; Kalucka U; Blø M; Furriol J; Gausdal G; Lorens J; Osman T; Marti HP
    Physiol Rep; 2021 Dec; 9(23):e15140. PubMed ID: 34877810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
    Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
    Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.
    Palisoul ML; Quinn JM; Schepers E; Hagemann IS; Guo L; Reger K; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
    Mol Cancer Ther; 2017 Dec; 16(12):2881-2891. PubMed ID: 28904132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
    von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
    Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
    Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
    Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I
    Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction.
    Landolt L; Furriol J; Babickova J; Ahmed L; Eikrem Ø; Skogstrand T; Scherer A; Suliman S; Leh S; Lorens JB; Gausdal G; Marti HP; Osman T
    Physiol Rep; 2019 May; 7(10):e14091. PubMed ID: 31134766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
    Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
    Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
    [No Abstract]   [Full Text] [Related]  

  • 10. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
    Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
    Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner.
    Zdżalik-Bielecka D; Kozik K; Poświata A; Jastrzębski K; Jakubik M; Miączyńska M
    Mol Cancer Res; 2022 Mar; 20(3):446-455. PubMed ID: 34782372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.
    Ludwig KF; Du W; Sorrelle NB; Wnuk-Lipinska K; Topalovski M; Toombs JE; Cruz VH; Yabuuchi S; Rajeshkumar NV; Maitra A; Lorens JB; Brekken RA
    Cancer Res; 2018 Jan; 78(1):246-255. PubMed ID: 29180468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ALK in pediatric RMS does not induce antitumor activity in vivo.
    Wierdl M; Tsurkan L; Chi L; Hatfield MJ; Tollemar V; Bradley C; Chen X; Qu C; Potter PM
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):251-263. PubMed ID: 29855693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma.
    Fleuren ED; Hillebrandt-Roeffen MH; Flucke UE; Te Loo DM; Boerman OC; van der Graaf WT; Versleijen-Jonkers YM
    Oncotarget; 2014 Dec; 5(24):12753-68. PubMed ID: 25528764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH.
    Grøndal SM; Tutusaus A; Boix L; Reig M; Blø M; Hodneland L; Gausdal G; Jackson A; Garcia de Frutos P; Lorens JB; Morales A; Marí M
    Front Immunol; 2024; 15():1400553. PubMed ID: 38817615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
    Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
    Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.
    Ciardiello D; Blauensteiner B; Matrone N; Belli V; Mohr T; Vitiello PP; Martini G; Poliero L; Cardone C; Napolitano S; De Falco V; Giunta EF; Ciaramella V; Corte CD; Barra G; Selvaggi F; Franco R; Marino FZ; Cuomo A; Morgillo F; Troiani T; Sibilia M; Ciardiello F; Martinelli E
    Med Oncol; 2021 Feb; 38(3):24. PubMed ID: 33570712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
    Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
    Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.